Creo Medical
Creo Medical, a pioneering medical device company headquartered in Great Britain, is at the forefront of advanced energy-based surgical solutions. Founded in 2015, the company has rapidly established itself in the medical technology industry, focusing on innovative treatments for gastrointestinal and oncological conditions. With a strong presence in Europe and expanding operations in the United States and Asia, Creo Medical is renowned for its unique combination of microwave and radiofrequency technologies. Their flagship products, including the CROMA™ and the Speedboat™ devices, offer minimally invasive options that enhance patient outcomes and reduce recovery times. Recognised for its commitment to innovation, Creo Medical has achieved significant milestones, positioning itself as a leader in the field of surgical endoscopy. The company continues to drive advancements in medical technology, making a meaningful impact on patient care worldwide.
DitchCarbon Score
How does Creo Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Creo Medical's score of 6 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Creo Medical's reported carbon emissions
In 2023, Creo Medical reported total carbon emissions of approximately 15,247,500 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions were about 46,500 kg CO2e, primarily from mobile combustion, while Scope 2 emissions totalled around 72,000 kg CO2e from purchased electricity. The most substantial impact came from Scope 3 emissions, which reached approximately 15,129,000 kg CO2e, largely due to business travel. In 2022, the company recorded total emissions of about 43,400 kg CO2e for Scope 1 and 8,300 kg CO2e for Scope 2, alongside 434,100 kg CO2e in Scope 3 emissions. This indicates a notable increase in emissions across all scopes from 2022 to 2023. Despite these figures, Creo Medical has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate pledges or science-based targets suggests that while the company is aware of its emissions, it may not yet have formalised a comprehensive strategy for emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | |
|---|---|
| Scope 1 | 46,500 |
| Scope 2 | 72,000 |
| Scope 3 | 15,129,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Creo Medical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
